-
Apr 23, 2026 Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
-
Apr 7, 2026 Apotex Strengthens Osteoporosis Care in Canada with Health Canada's Approval of DENOZA™, a Denosumab Biosimilar
-
Mar 30, 2026 Apotex announces leadership changes
-
Mar 25, 2026 Apotex Expands Canadian Ophthalmology Portfolio with Health Canada’s Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)
-
Feb 5, 2026 Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal
-
Nov 17, 2025 Apotex donation helps Oak Valley Health respond to urgent capacity needs amid rapid community growth
-
Oct 23, 2025 Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
-
Oct 8, 2025 Apotex supports launch of home-based cancer care with $1.5M donation
-
Oct 7, 2025 Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
-
Jul 2, 2025 Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
-
May 20, 2025 Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
-
May 1, 2025 Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
-
Mar 27, 2025 Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
-
Feb 24, 2025 Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
-
Feb 13, 2025 Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
-
Feb 5, 2025 Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
-
Feb 5, 2025 Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride)
-
Feb 3, 2025 Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company
-
Jan 31, 2025 Voluntary Recall of five ( 5 ) lots of APO-QUETIAPINE XR (quetiapine fumarate extended-release tablets)
-
Dec 10, 2024 Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Nov 17, 2026
Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
TORONTO, ON, November 16, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced the launch of APO-LINAGLIPTIN™ (linagliptin tablets), the latest addition to its portfolio of medicines.
-
Nov 12, 2026
Apotex Announces Second Quarter 2027 Results
TORONTO, ON, November 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada’s largest pharmaceutical company, today announced its financial and operating results for the three and six months ended September 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.